One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.